Compare Novavax Inc (NVAX) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $433 (market cap $2.03T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 1208.3× Novavax Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.93% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TSM | |
|---|---|---|
Market Cap | $1.68B | $2.03T |
Sector | Health | Technology |
52-Week High | $11.19 | $477.57 |
52-Week Low | $6.22 | $258.91 |
Enterprise Value | $1.26B | $1.95T |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
TSM trades at $439.00, up 2.35% with strong bullish momentum. The stock shows robust fundamentals with 44.56% net margin and consistent earnings beats. Technical indicators signal bullish momentum with price near pivot point support. Recent news highlights TSMC's dominant 73% foundry market share and AI-driven growth prospects, with analyst consensus strongly bullish.
Outlook remains positive with 72% analyst buy ratings and $541.29 price target representing 23% upside. Key risks include geopolitical tensions and capital-intensive expansion, but strong cash flow generation and AI semiconductor demand support continued growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
